Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089843 · ClinicalTrials.gov registry record · Phase 2
Bone Loss in Women With Anorexia Nervosa
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00089843: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00089843 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089843, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
Women with Anorexia Nervosa have been found to have low bone density. The study will determine whether administration of low doses of a natural hormone, testosterone and/or risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in this condition.
Interventions
- DRUG Testosterone
- DRUG Actonel (risedronate)
- DRUG Placebo Actonel (risedronate)
- DRUG Placebo testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089843
The ClinicalTrials.gov registry entry for NCT00089843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Testosterone is the first listed.
NCT00089843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089843 about?
NCT00089843 is a clinical study titled "Bone Loss in Women With Anorexia Nervosa". Women with Anorexia Nervosa have been found to have low bone density. The study will determine whether administration of low doses of a natural hormone, testosterone and/or risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in this condition.
What is the current status of trial NCT00089843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2003-06. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00089843?
The interventions under investigation include: Testosterone (DRUG), Actonel (risedronate) (DRUG), Placebo Actonel (risedronate) (DRUG), Placebo testosterone (DRUG).
Who is sponsoring clinical trial NCT00089843?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.